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Abstract
Background: Standard therapy for borderline-resectable pancreatic cancer in the UK is surgery with adjuvant
chemotherapy, but rates of resection with clear margins are unsatisfactory and overall survival remains poor.
Meta-analysis of single-arm studies shows the potential of neo-adjuvant chemo-radiotherapy but the relative radio-
resistance of pancreatic cancer means the efficacy of conventional dose schedules is limited. Stereotactic
radiotherapy achieves sufficient accuracy and precision to enable pre-operative margin-intensive dose escalation
with the goal of increasing rates of clear resection margins and local disease control.
Methods/Design: SPARC is a “rolling-six” design single-arm study to establish the maximum tolerated dose for
margin-intensive stereotactic radiotherapy before resection of pancreatic cancer at high risk of positive
resection margins. Eligible patients will have histologically or cytologically proven pancreatic cancer defined as
borderline-resectable per National Comprehensive Cancer Network criteria or operable tumour in contact with
vessels increasing the risk of positive margin. Up to 24 patients will be recruited from up to 5 treating centres
and a ‘rolling-six’ design is utilised to minimise delays and facilitate ongoing recruitment during dose-
escalation. Radiotherapy will be delivered in 5 daily fractions and surgery, if appropriate, will take place 5–6
weeks after radiotherapy. The margin-intense radiotherapy concept includes a systematic method to define the
target volume for a simultaneous integrated boost in the region of tumour-vessel infiltration, and up to 4
radiotherapy dose levels will be investigated. Maximum tolerated dose is defined as the highest dose at which
no more than 1 of 6 patients or 0 of 3 patients experience a dose limiting toxicity. Secondary endpoints
include resection rate, resection margin status, response rate, overall survival and progression free survival at 12
and 24 months. Translational work will involve exploratory analyses of the cytological and humoral
immunological responses to stereotactic radiotherapy in pancreatic cancer. Radiotherapy quality assurance of
target definition and radiotherapy planning is enforced with pre-trial test cases and on-trial review. Recruitment
began in April 2015.
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Discussion: This prospective multi-centre study aims to establish the maximum tolerated dose of pre-operative
margin-intensified stereotactic radiotherapy in pancreatic cancer at high risk of positive resection margins with
a view to subsequent definitive comparison with other neoadjuvant treatment options.
Trial registration: ISRCTN14138956. Funded by CRUK
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Background
Pancreatic cancer is responsible for only 3 % of cancer
diagnoses but 5 % of cancer deaths, making it the fifth
leading cause of cancer death in the UK (9408 cases in
2013 and 8817 deaths in 2014) [1]. Radical surgical re-
section represents the only chance of long-term disease
control, but was possible for just 8 % of UK patients di-
agnosed in 2006–2010 [2]. In Europe standard practice
for resectable disease is surgery followed by chemother-
apy, but for these patients median survival is only
24 months and 50 % of patients will suffer local recur-
rence [3] suggesting that further improvement in multi‐
modal therapy is required.
The failure to consistently achieve microscopic surgical
clearance contributes to the high rates of disease relapse:
alongside tumour size, grade and lymph node metastases,
resection margin involvement has been repeatedly shown
to predict long-term survival [4–6]. Accurate margin as-
sessment requires comprehensive examination of the sur-
gical specimen and rates of margin involvement are
higher when a standardised protocol is used [7]. Despite
centralization of services and improvement in diagnostic
radiology, positive margins were reported in >35 % of pa-
tients in the largest multi‐national adjuvant trial in pan-
creatic cancer involving over 1000 patients (ESPAC 3),
which again reinforced that patients with positive margins
have poor outcome (hazard ratio 1.35, 95 % confidence
interval 1.17‐1.56, p < 0.001) [8].
A small proportion of patients present with pancreatic
tumours that can be classified as “borderline-resect-
able”, defined by a limited extent of vascular invasion.
For these patients resection is possible but is likely to
require vascular reconstruction and there is an espe-
cially high risk of positive resection margins, reported
to be 62.9 % in the UK [9]. The concept of Borderline
Resectable Pancreatic Cancer (BRPC) was initially de-
scribed in 2001 by Mehta et al., describing 15 cases ini-
tially assessed as “marginally resectable” but where
resectability was improved with preoperative chemo-
radiotherapy [10]. The definition of BRPC was refined
by an AHPBA/SSO/SSAT consensus statement [11, 12],
now adopted by the NCCN [13]:-
 Venous involvement of the SMV or PV with
distortion or narrowing of the vein or occlusion of
the vein with suitable vessel proximal and distal,
allowing safe resection and reconstruction
 Gastro‐duodenal artery encasement up to hepatic
artery with either short segment encasement or
direct abutment of the hepatic artery, without
extension to the celiac axis
 Tumour abutment of the SMA not to exceed greater
than 180° of the circumference of the vessel wall.
An alternative definition of BRPC by the MDACC has
not been as widely recognised [14]. A multidisciplinary
team approach is needed to assess the likelihood of
attaining negative margins and this should remain the
key consideration in determining if a patient is a poten-
tial candidate for resection [14, 15].
The management of BPRC is controversial, and there
is increased interest in pre-operative treatment strat-
egies that may improve outcomes [16]. Theoretical ad-
vantages include a greater chance of delivering full
dose treatment, while drawbacks include possible over-
treatment of resectable disease, the need for a biopsy
and stent to relieve obstruction while awaiting surgery.
Many patients presenting with localised disease de-
velop frank metastases shortly after diagnosis and if
this occurs during induction therapy these patients can
be spared inappropriate and futile surgery [14].
Pre-operative (chemo) radiotherapy aims to treat the
tumour in situ to achieve tumour regression and facili-
tate curative resection. This approach has become
standard of care for some tumour sites, having been
shown to reduce local recurrence in rectal cancer [17],
and increase overall survival in oesophageal cancer
[18], but is not established in pancreatic cancer due to
limited effectiveness of standard dose schedules, des-
pite potential advantages over postoperative treatment
[19]. A complete tumour response is only seen in around
5 % of patients [20], though a larger proportion of patients
(35 %) benefit from tumour down-staging to achieve resect-
ability [21] and patients who successfully complete neoad-
juvant chemoradiotherapy and go on to have resection tend
to have high rates of clear resection margins [22, 23] and
reduced rates of local recurrence [24, 25].
Stereotactic body radiation therapy (SBRT) combines
rigorous immobilisation and image-guidance with hypo-
fractionation, to reduce radiotherapy planning margins
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and treat small targeted volumes with greater accuracy
and precision, supporting safe delivery of much higher
biologically effective doses. It has been shown to be a
highly-effective local treatment option in unresectable
pancreatic cancer with high rates of local control
achieved using treatment delivered in a single exposure
[26–29], and when treatment was delivered in 3–5 frac-
tions lower rates of toxicity were seen without com-
promising disease control [30–35].
The specific goal in treating BRPC with pre-operative
radiotherapy will be improve the chances of achieving
clear resection margins, reduce risk of local recurrence
and achieve chances of long-term survival similar to
those for patients with initially resectable tumours.
Neoadjuvant treatment has been shown to be deliver-
able and effective in BRPC, such as in a series of 160
patients described by Katz et al., among whom 78 %
completed preoperative therapy and restaging, and
41 % underwent pancreatectomy, with a 94 % rate of
clear margins [36].
The premise of the SPARC trial is a Margin-Intense
radiotherapy concept where the whole tumour is
treated to a minimum dose while a simultaneous inte-
grated boost (SIB) is used to deliver additional dose
to the margin of tumour around structures such as
the superior mesenteric artery (SMA), SMV or portal
vein and retroperitoneal margin. This approach com-
plements surgery as these are the most difficult mar-
gins to resect and are at highest risk of positive
surgical margins. Prospective dose-escalation aims to
establish the maximum tolerated dose for this treat-
ment paradigm for subsequent definitive investigation
of efficacy. Once the maximum tolerated dose (MTD)
is established this will provide a platform to integrate
with optimal systemic treatment.
Methods/Design
Study design
The SPARC trial is a phase I dose-escalation study using
the rolling six design [37] to establish MTD of SBRT de-
livered in the pre-operative setting for borderline resect-
able pancreatic cancers. This method minimises delays
in the dose escalation phase [37]. Patients will complete
SBRT in approximately one week and surgery will take
place 5–6 weeks after radiotherapy. Patients will be on
the study for 36 weeks from registration to end of treat-
ment visit followed by standard care for two years post
SBRT day one for the last patient, or when all partici-
pants have died.
The trial opened in April 2015 and will recruit up to
24 patients from five UK centres (Oxford, Glasgow,
Leeds, Newcastle and Nottingham). The SPARC trial is
conducted in accordance with the Helsinki Declaration
(1996) and the regulatory requirements for clinical trials
of an investigational medicinal product under the Euro-
pean Union Clinical Trials Directive. The trial is ap-
proved by the National Research Ethics Service
Committee South Central – Oxford B (REC reference:
15/SC/0059) and is sponsored by the University of Ox-
ford, with funding from Cancer Research UK. Data sub-
mission for the SPARC trial is via electronic submission
into the online database system OpenClinica by site
staff. The Oncology Clinical Trial Office (OCTO) coor-
dinates and manages the trial while the Centre for Statis-
tics in Medicine (University of Oxford) will perform all
statistical analysis.
Participants
The inclusion and exclusion criteria for the SPARC trial
are summarised in Table 1.
Interventions
At registration patients are assigned to the appropriate
SBRT dose level (Table 2) and will receive 5 fractions of
SBRT over 5–8 days. The dose schedules selected have
been designed to achieve approximately equivalent dose
to the tumour to that used in conventionally fraction-
ated radical radiotherapy (50-66Gy in 2Gy fractions)
while the dose selected for the ‘at risk volume’ (area at
risk of positive margin) is higher, to achieve increased
likelihood of ablation of tumour cells. A maximum of 4
dose levels (including one de-escalated dose level) are
expected to be needed to establish the MTD.
Dose level assignment will be based on the number of
dose limiting toxicities (DLTs) observed, and the number
of patients have no DLTs yet, but are still in the DLT as-
sessment period as defined in the outcome measure
below (i.e., toxicity data pending/evaluable not yet). In
this trial design, the first two patients are treated at level
1. The third patient will be treated at level −1 if two
DLTs have been observed. If at least one patients en-
rolled is not evaluable yet and less than 2 DLTs have
been observed, this third patient will be entered at the
same dose level, Level 1. For the fourth patient, if tox-
icity data is pending for at least one of the patients en-
rolled, the fourth patient will be allocated to the same
dose level. But, if there are two or more DLTs when the
fourth patient enters the study, the dose level will be de-
escalated. The dose level will be escalated if there is no
DLT after the first three patients finish the DLT assess-
ment period. This process will be repeated for patients
five and six. After the sixth patient is enrolled to a dose
cohort, accrual will be only temporarily suspended until
toxicity data is fully available for these six patients and/
or a decision from the Trial Management Group (TMG)
is made. Recruitment will stop once the MTD is
identified.
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Outcome measures and definitions
The primary endpoint of the SPARC study is MTD, de-
fined as the highest level of SBRT at which no more than
1 of 6 patients or 0 of 3 patients experiences a DLT in
the period from starting SBRT to one month post-
surgery or one month after the evaluation in week 3
post-SBRT if no surgery takes place. DLT is defined as
these possible adverse events (AEs) (according to
CTCAE v4.03), seen in the DLT assessment period:
1. ≥ Grade 3 upper gastro-intestinal (GI) bleeding
2. ≥ Grade 4 nausea/vomiting uncontrolled after 48 h of
standard treatment
3. ≥ Grade 4 pancreatitis not stent related
4. Interruption of SBRT >1 week due to SBRT-related AEs
5. ≥ Grade 4 vascular events: SMV thrombosis, bowel
ischaemia due to SMA arteritis/stenosis, friable
vessels at surgery
6. Other AEs that the TMG agrees to be dose limiting
and possibly related to SBRT such as ≥ grade 3
gastrointestinal fistula >30 days after surgery
Secondary outcomes include resection rate, resection
margin status rates, rate of pathological complete re-
sponse, late SBRT toxicity, efficacy and long term
safety. Resection rate is defined as the proportion of
patients with radical oncological resection of pancre-
atic cancer over the total enrolled patients. Resection
margin status (R0/R1/R2) is defined according to the
standards of the Royal College of Pathologists, and re-
sponse rate is defined as the rate of patients with
pathological complete response over the total enrolled
patients. Late toxicity is defined as any GI AE/other
AE > grade 2 occurring between 1 month and 6 month
post-surgery. Additional secondary outcomes include
efficacy and long term safety as indicated by progres-
sion free survival (PFS) and overall survival (OS). PFS
is defined as the time from date of first SBRT dose to
the first date of progression or death for any cause, or
is censored at the date of last known follow-up date if
they are not observed to die during the course of the
trial. OS is defined as the time from date of first SBRT
dose to the date of death for any cause or is censored
at the last known follow-up date. Exploratory out-
comes include relationships between imaging and
pathology (treatment response and resection margin
status) and changes in markers of the innate and adap-
tive immune response before and during SBRT (cyto-
logical assessments and levels of interferon-related
RNA).
Table 1 SPARC Inclusion/Exclusion criteria
Inclusion criteria Exclusion criteria
1. Borderline resectable localised tumour of the pancreatic head/uncinate
process/body as per NCCN Guidelines (tumours of the tail of pancreas
are not eligible for inclusion) or operable tumour in contact with vessels
increasing the risk of positive margin as defined by CT +/− MRI +/− PET
criteria within 28 +/− 7 days prior to trial entry, de novo or following
systemic treatment.
2. Histologically proven pancreatic ductal adenocarcinoma or cytological
proven pancreatic malignancy
3. Able to undergo biliary drainage using a stent
4. Deemed fit and suitable for surgical resection.
5. No overt metastases or uncertain status with investigations suspicious
of possible metastatic disease (e.g., small equivocal pulmonary nodule(s)).
6. Male or female, Age ≥16 years
7. Life expectancy of at least 6 months
8. ECOG performance status 0–1
9. The patient is willing and able to comply with the protocol for the duration
of the study, and scheduled follow-up visits and examinations
10. Written (signed and dated) informed consent and be capable of
co-operating with protocol
11. Haematological and biochemical indices within specified ranges.
1. Definitive metastatic disease or local disease that cannot be
encompassed in the SBRT field.
2. History of previous or concurrent malignancy diagnoses for which
the expected prognosis is likely to be worse than that of the current
diagnosis of pancreatic cancer (excludes for example: e.g., localised
prostate cancer, early colorectal cancer, early breast cancer,
curatively-treated basal cell carcinoma of skin, carcinoma in situ of
cervix; curatively treated cancer of other sites who are recurrence
free for >3 years).
3. Serious medical or psychological condition precluding trial
intervention.
4. Previous upper abdominal or right chest wall radiotherapy where
30 % of the liver has received >15Gy.
5. Pregnancy: Pregnant or breast-feeding women are ineligible.
Women of childbearing potential must use effective methods of
contraception.
6. Any other psychological, social or medical condition, physical
examination finding or laboratory abnormality that the Investigator
considers makes the patient a poor trial candidate or could interfere
with protocol compliance or the interpretation of the trial results.
Table 2 Radiotherapy dose escalation levels
Radiotherapy
dose level
Tumour (PTV) Area at risk of R1 (PTV_R)
Dose/# [Gy] Total dose [Gy] *BED [Gy10] EQD2 [Gy] Dose/# [Gy] Total dose [Gy] *BED [Gy10] EQD2 [Gy]
Level −1 6 30 50 40 8 40 72 60
Level 1 6 30 50 40 9 45 88 71.5
Level 2 6.5 32.5 56 45 9.5 47.5 92 77.2
Level 3 7 35 62 50 10 50 100 83.3
*BED [Gy10] biologically effective dose for acute reacting tissues (α/β = 10), EQD2 equivalent dose in 2-Gy fractions
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Sample size considerations
Patient numbers will be determined by the primary end-
point of establishing the MTD, which will require a
maximum of 24 evaluable patients. An evaluable patient
for primary endpoint analysis is defined as one who has
received at least one fraction of SBRT and experiences a
DLT, or a patient who has received at least four fractions
of SBRT and is assessed one month post-surgery (or
assessed at similar time for DLT if no surgery). Patients
not evaluable for primary endpoint will be replaced, but
a patient who does not become evaluable for the primary
endpoint may continue to be followed up for surgical
outcome, PFS and OS as appropriate, unless consent is
withdrawn.
Statistical analysis
All analyses will follow a statistical analysis plan written in
accordance with current standard operating procedures.
Baseline characteristics will be summarised (number/fre-
quency) for all enrolled patients. Patients who died or
withdrew before treatment started or fail to complete the
required safety observations will be described separately.
Primary MTD analysis will concern the frequency of pa-
tients with no DLT according to dose-escalation of SBRT.
Descriptive statistics will summarise the DLT’s and safety
variables with patients grouped according to dose level re-
ceived. Secondary outcomes (resection rate, resection
margin status and response rate) associated with SBRT
will be summarised by descriptive statistics along with
numbers and percentages. Late toxicity will be sum-
marised by descriptive statistics for all patients who re-
ceived at least one dose of SBRT treatment. Physical
exam, haematology and biochemistry data will be sum-
marised across time. Both PFS and OS estimates at one
and two years and 90 % CI will be provided together with
median estimates. A Kaplan-Meier curve will be plotted
with 90 % CI. A trial summary will record patient recruit-
ment and trial decision-making.
Monitoring committees
The Radiotherapy and Imaging Trials Oversight Commit-
tee (RIOC) is the independent committee for SPARC cov-
ering both data management committee and oversight
responsibilities as delegated by the Sponsor and will meet
at least once annually to review and ratify substantial
decisions.
Discussion
This study builds on the current evidence base in SBRT
for pancreatic cancer, which has so far been largely used
in the locally advanced setting with promising results
and aims to take it a step further by prospectively evalu-
ating the safety and benefit of pre‐operative margin-
intense SBRT.
A five-fraction schedule aims to optimise the balance
of short duration and tumouricidal biologically-effective
dose to the tumour with acceptable risk of late normal
tissue injury. Potential clinical benefits of a significantly
hypofractionated radiotherapy regimen compared with a
protracted conventional 6-week course of chemoradio-
therapy include a shorter enforced delay to definitive
surgery or alternatively more straightforward integration
with systemic therapy regimens.
The concept of margin‐intensive therapy aims to fur-
ther improve local control without increasing toxicity, as
the region of integrated boost tends not to overlap with
the major dose-limiting organ at risk (duodenum) help-
ing to make safe dose-escalation to this sub-volume pos-
sible. Normal-tissue dose-volume constraints retain
priority but where there is overlap, only the dose to the
overlapping region is constrained as necessary, enabling
the non-overlapping portion of the target volume to re-
ceive the prescribed dose (see Fig. 1).
The optimal pre-operative therapy in pancreatic can-
cer has not been identified, and could involve chemo-
therapy, radiotherapy or both. The national multicentre
study ESPAC‐5 F is currently open to recruitment in the
UK with the primary aim to establish the feasibility of
recruiting patients with BRPC to be randomised between
two pre‐operative chemotherapy regimens (GEMCAP
and FOLFIRINOX), pre‐operative CRT and standard of
care (surgery followed by adjuvant chemotherapy) (38),
therapy options which would then require definitive
comparative evaluation in a subsequent larger study.
Two single-institution retrospective reviews report
outcomes for the use of SBRT in patients with BRPC,
both of which show high rates of subsequent successful
surgical resection with clear margins [38, 39]. Rajagopa-
lan et al. [38] report on 12 resected patients, of which 7
were deemed BRPC using.
MDACC criteria. Most patients received Gemcitabine-
based systemic chemotherapy. The SBRT consisted of
24–36 Gy in 3 fractions, surgery took place at a median
3.3 months (range 1.5 – 6.6 months) and 11/12 patients
had an R0 resection. Chuong et al. [39] treated 73 pa-
tients (of which 57 were deemed BRPC using NCCN cri-
teria) with systemic Gemcitabine-based chemotherapy
and 5-fraction SBRT. Median dose prescribed was 35 Gy
to the tumour margin and no less than 25 Gy to the en-
tire pancreatic tumour. 44/57 BRPC cases underwent ex-
ploratory resection and 31/32 resected cases had an R0
resection. No acute toxicity > grade 3 occurred and 5.3 %
(4 patients with locally advanced inoperable disease) ex-
perienced late grade 3 toxicity (3 GI bleeding and 1 an-
orexia). With a median FU of 10.5 months (2.2‐
25.9 months) the median OS was 16.4 months in all
BRPC patients, with median OS of 19.3 months in
resected patients. Disappointing overall survival rates in
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published series (median overall survival 5–20 months)
are attributed to variable provision of optimal systemic
treatment.
Evidence is growing for the importance of Radiation
Therapy Quality Assurance (RTQA) for clinical trial in-
terpretation as well as patient outcomes [40]. The
SPARC trial incorporates a comprehensive prospective
RTQA programme with a detailed radiotherapy protocol
and atlas that was supported by a pre-trial workshop for
collaborating clinicians, both of which have been shown
to reduce variation in target volume definition [41–43].
A pre-trial test case of contouring and planning must be
completed satisfactorily by recruiting centres and RTQA
will continue with on-trial peer review prior to treat-
ment supported by web-conferencing facilities.
The trial originally opened with eligibility criteria that
excluded patients with suspicion of metastatic disease,
those who may not be fit for surgical resection, and
those who had received induction chemotherapy, which
has become more common practice since the study was
initially designed. Many patients presenting to our
centre with BRPC were rendered ineligible for these rea-
sons, and during the first year that the trial was open
only one patient was successfully recruited. The primary
endpoint of the study is the assessment of the safety and
tolerability of the intervention, and therefore the patient
eligibility inclusion and exclusion criteria for the study
were revised to the current version published here, with
the aim of improving patient recruitment.
Exploratory immunological investigations
Preclinical evidence suggests radiotherapy generates an
immunological response, which can contribute to the ef-
ficacy of treatment. Direct damage and local inflamma-
tion increases antigen presentation to stimulate adaptive
immune responses, and radiotherapy delivered in larger
fractions has been shown to particularly enhance this
effect [28]. In the SPARC study a panel of immuno-
logical tests to examine innate and adaptive immune re-
sponses to pancreatic SBRT. These preliminary data will
be explored for their utility as predictive bio‐markers in
future studies.
Conclusion
The non‐interventional phase of follow‐up after the last
patient last visit at the end of study will permit an esti-
mate of the efficacy of pre‐operative SBRT on overall
survival and progression free survival to be observed.
Once the MTD has been defined in this phase I trial, a
phase II study will definitively evaluate efficacy end‐
points. If positive, subsequent randomised phase III in-
vestigations will be required to assess superiority of this
treatment strategy alone or integrated with pre-operative
systemic treatment over surgery alone for this patient
group.
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